Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Transcenta Holding Ltd

Transcenta Holding Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.01
  • Today's Change0.01 / 1.00%
  • Shares traded100.50k
  • 1 Year change-74.75%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Transcenta Holding Ltd is a investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company also provides contract development and manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.

  • Revenue in HKD (TTM)24.38m
  • Net income in HKD-391.65m
  • Incorporated2010
  • Employees200.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wai Yuen Tong Medicine Holdings Limited783.88m-26.68m227.27m810.00--0.17062.780.2899-0.0228-0.01320.66361.180.17210.400110.55967,754.30-0.1597-0.3053-0.2538-0.520650.3743.82-0.928-2.181.372.130.2879--8.330.8488-62.16--15.35--
PuraPharm Corp Ltd419.41m-87.09m273.17m525.00--2.09--0.6513-0.2205-0.22051.060.32960.48541.155.93633,542.30-10.08-9.20-30.69-19.7051.9759.52-20.77-19.330.3116-1.420.7597---9.20-11.4111.76---13.68--
Hin Sang Group (Interntnl) Hldng Co Ltd92.62m-36.71m289.33m247.00--1.39--3.12-0.0336-0.03360.08480.19130.15362.3410.34374,967.60-6.04-5.11-9.78-7.0461.9859.72-39.30-28.420.1287-1.680.6054--13.70-12.8325.84---69.21--
Uni-Bio Science Group Ltd508.40m98.86m406.80m458.004.161.303.420.80020.01590.01590.08120.05071.272.2312.211,249,140.0024.761.4632.971.9783.5180.5919.441.232.17168.550.22670.0010.0829.0884.04--84.98--
Tianda Pharmaceuticals Ltd384.68m-47.26m408.51m695.00--0.7502--1.06-0.022-0.0220.17890.25330.43412.974.46445,745.10-5.34---7.97--45.83---12.30--0.6748-9.510.1536--------------
Transcenta Holding Ltd24.38m-391.65m439.13m200.00--0.4148--18.01-0.9645-0.96450.06012.430.01310.81060.5768113,414.40-21.08---29.77--26.02---1,606.19--1.04-31.650.2826---47.15---13.72------
3D Medicines Inc533.81m-491.11m593.88m193.00--0.6414--1.11-2.09-2.092.243.590.37464.945.792,695,996.00-37.27---50.88--91.97---99.50--2.56--0.2517--11.91--48.78------
Data as of Nov 01 2024. Currency figures normalised to Transcenta Holding Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.96%Per cent of shares held by top holders
HolderShares% Held
Fullerton Fund Management Co. Ltd.as of 31 Dec 202326.02m5.96%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.